Key result
Warfarin-associated intracerebral hemorrhage with therapeutic INR was associated with higher 3-month mortality compared to non-OAC-associated hemorrhage (51% vs 29%; OR 3.59, 95% CI 1.50-8.60).
Why the study?
Does oral anticoagulation use and higher baseline INR increase 3-month mortality in patients with intracerebral hemorrhage?
Cohort (n=1,013)
No
Does oral anticoagulation use and higher baseline INR increase 3-month mortality in patients with intracerebral hemorrhage?
Odds Ratio: 3.59 (95% CI 1.5–8.6)
Absolute Event Rate: 51% vs 29%
In patients with intracerebral hemorrhage, prior warfarin use and higher baseline INR are associated with larger hematomas, more severe strokes, and significantly increased 3-month mortality compared to non-anticoagulated patients.
Elevated INR was associated with higher mortality in warfarin-ICH; leaves open optimal reversal thresholds for prospective trials.
BACKGROUND AND PURPOSE: Intracerebral hemorrhage (ICH) is the most feared complication of oral anticoagulation (OAC). Our aim was to investigate the impact of the international normalized ratio (INR) level on mortality in OAC-associated ICH compared with non-OAC-associated ICH. METHODS: A retrospective chart review of consecutive ICH patients treated at the Helsinki University Central Hospital from January 2005 to March 2010 (n = 1013) was performed. An ICH was considered to be OAC-associated if the patient was on warfarin at ICH onset. The association of INR with 3-month mortality was adjusted in a multivariable logistic regression model for factors influencing the crude odds ratios (ORs) in bivariable logistic regression by more than 5%. RESULTS: One in eight ICHs was OAC-associated (n = 132). Of these, 50% had therapeutic INR (2.0-3.0), 7% had INR <2.0 and 43% had high INR (>3.0) on admission. Patients on OAC were older (median 76 vs. 66 years; P < 0.001) with more severe symptoms (median National Institutes of Health Stroke Scale 14 vs. 10; P < 0.001) and larger hematomas (median 11.4 vs. 9.7 ml; P < 0.001) on admission than patients not on OAC. After adjustment for confounders, 3-month mortality in the whole cohort was associated with higher baseline INR (OR 1.06; CI 1.03-1.09 per 0.1 increment). Mortality was higher with both therapeutic (51% at 3 months; OR 3.59; CI 1.50-8.60) and high (61%; OR 5.26; CI 1.94-14.27) INR values compared with non-OAC-associated ICH (29%). CONCLUSIONS: Patients with OAC-associated ICH had more severe strokes and higher mortality compared with patients with ICH not related to OAC. Higher baseline INR was associated with increased 3-month mortality.
No takes yet. Share an insight, caveat, or question.
Curtze et al. (2014) conducted a cohort in Intracerebral hemorrhage (n=1,013). Warfarin use with therapeutic INR vs. Non-OAC-associated intracerebral hemorrhage was evaluated on 3-month mortality (OR 3.59, 95% CI 1.50-8.60). Warfarin-associated intracerebral hemorrhage with therapeutic INR was associated with higher 3-month mortality compared to non-OAC-associated hemorrhage (51% vs 29%; OR 3.59, 95% CI 1.50-8.60).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: